As of Friday close, Vistagen Therapeutics Inc.’s (NASDAQ:VTGN) stock was down -$0.04, moving down -0.72 percent to $5.50. The average number of shares traded per day over the past five days has been 1,347,940 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.92 fall in that time frame. In the last twenty days, the average volume was 4,990,340, while in the previous 50 days, it was 2,157,906.
Since last month, VTGN stock rose 194.12%. Shares of the company fell to $1.63 on 08/04/23, the lowest level in the past month. A 52-week high of $24.71 was reached on 08/07/23 after having rallying from a 52-week low of $1.62. Since the beginning of this year, VTGN’s stock price has risen by 77.99% or $2.41, and marked a new high 13 times. However, the stock has declined by -77.74% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
VTGN stock investors should be aware that Vistagen Therapeutics Inc. (VTGN) stock had its last reported insider trading activity 12 days ago on Aug 07. COMMODORE CAPITAL LP, the 10% Owner of the company, purchased of 775,756 shares for $23.15 on Aug 07. It resulted in a $17,961,079 investment by the insider.
Financial Health
In the recent quarter, Vistagen Therapeutics Inc.’s quick ratio stood at 3.80, while its current ratio was 3.80, showing that the company is able to pay off its debt. Based on annual data, VTGN earned $59.04 million in gross profit and brought in -$0.23 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. During the quarter, the company generated -$6.97 million in EBITDA. The liabilities of Vistagen Therapeutics Inc. were 8.18 million at the end of its most recent quarter, and its total debt was $3.28 million. The value of shareholders’ equity is $9.36 million.
Technical Picture
This quick technical analysis looks at Vistagen Therapeutics Inc.’s (VTGN) price momentum. With a historical volatility rate of 277.09%, the RSI 9-day stood at 52.23% on 18 August.
With respect to its five-day moving average, the current Vistagen Therapeutics Inc. price is down by -14.33% percent or -$0.92. At present, VTGN shares trade +195.70% above its 20-day simple moving average and +26.96% percent above its 100-day simple moving average. However, the stock is currently trading approximately +102.95% above its SMA50 and +38.26% above its SMA200.
Stochastic coefficient K was 17.06% and Stochastic coefficient D was 18.49%, while ATR was 1.76. Given the Stochastic reading of 16.77% for the 14-day period, the RSI (14) reading has been calculated as 54.49%. As of today, the MACD Oscillator reading stands at -0.91, while the 14-day reading stands at -0.03.
Analyst Ratings
Maxim Group upgraded its rating on Vistagen Therapeutics Inc. (NASDAQ: VTGN) to a Buy in a note to investors on August 07, 2023. The analysts firm previously had a Hold rating on the stock.Vistagen Therapeutics Inc. (VTGN) has been rated Buy by analysts. According to 0 brokerage firms, VTGN is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Vistagen Therapeutics Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $30.00, the current consensus forecast for the stock is $30.00 – $30.00. Based on these forecasts, analysts predict Vistagen Therapeutics Inc. (VTGN) will achieve an average price target of $30.00.
